Home >
FEATURED COMMENTARY
04 Aug 2015 01:12 PM
Clinical investigation forms the backbone and the history of medical oncology. Cancer clinical trials provide the evidence we need to demonstrate safety and efficacy before Food and Drug...
31 Aug 2015 02:19 PM
By Daniel B. Hinshaw, MD Member, Palliative Care in Oncology Symposium Program and Steering Committees
31 Aug 2015 01:39 PM
She had come to see me as a second opinion; diagnosed with uterine serous cancer, one of the more aggressive types of uterine cancers. At surgery they found that it had metastasized to her nodes—...
21 Aug 2015 08:03 AM
My patient mix comes in waves—some months it is mostly women with breast cancer struggling with adjuvant endocrine therapy or men in the aftermath of...
16 Aug 2015 01:37 PM
Sometimes, it seems like the easiest way to raise some physician’s hackles is to bring up something that “administration” is doing. Maybe it’s a practice change felt to make things run more smoothly...
13 Aug 2015 11:25 AM
The good kind of problem is having too many choices; the bad kind of problem is having too few choices. Today, I am writing about the ultimate in the good kind of problems: Being an exceptional...
05 Aug 2015 09:49 AM
It is difficult (but not impossible) to reflect on the fact that one of the key reasons I went into medical oncology was the...
04 Aug 2015 01:52 PM
I’m sure I am not alone in saying that I am almost obsessively conscious of time. Namely, that there never seems to be enough of it. As busy oncologists, we all have constant demands on our time,...

Latest Comments & Discussions


Pamela Breakey
31 Aug 2015 01:30 PM
I don't know if I am an "exceptional responder" but I alive and don't "look like a cancer patient" 11 1/2 years after being diagnosed with...

ASCO University
26 Aug 2015 10:11 AM
Thank you to Drs. Greco and Nardi leading the discussion of this case and also to all of those who contributed to the conversation! The...

F Anthony Greco, MD
26 Aug 2015 10:09 AM
Course Faculty Summary I would also like to thank everyone for participating in this discussion. Below are my thoughts based on the...

Valentina Nardi
26 Aug 2015 10:08 AM
Course Faculty Summary Thank you for everyone who participated in this discussion. My summary thoughts for each case are below: In...

F Anthony Greco, MD
25 Aug 2015 09:18 AM
Course Faculty Response Good question. Although there are no data for ALK inhibitors in the adjuvant setting, for ALK rearranged lung...

Pages

Most Read

She had come to see me as a second opinion; diagnosed with uterine serous cancer, one of the more aggressive types of uterine cancers. At surgery they found that it had metastasized to her nodes—stage III disease.
Lab studies have shown that gastric cancer cell lines with low levels of ataxia telangiectasia mutated (ATM)—which plays a key role in activating the repair response to DNA damage—are particularly sensitive to olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP inhibitors target tumors...
This year’s Community Research Forum Annual Meeting is right around the corner. As Chair of the CRF Council, I am very excited about the Meeting and would like to invite you to participate in this unique opportunity.
Chief of the Melanoma and Immunotherapeutics Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC); Associate Director of the Ludwig Center for Cancer Immunotherapy at MSKCC; Associate Professor at Weill Cornell Graduate School of Medical Sciences and Weill Cornell...
My patient mix comes in waves—some months it is mostly women with breast cancer struggling with adjuvant endocrine therapy or men in the aftermath of surgery for prostate...

Tweets from ASCO

Tweets from Oncology Community